

Prognostic factors and early risk-adapted therapy in patients with chronic lymphocytic leukemia in Binet stage A

Submission date 31/08/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 06/10/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 12/02/2020	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Michael Hallek

Contact details
Kerpenerstr. 62
Cologne
Germany
50924

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
CLL1

Study information

Scientific Title

-

Study objectives

1. Identification of a group of high risk patients in Binet stage A
2. Evaluation of the efficacy of an early risk-adapted therapy in Binet stage A patients

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Chronic Lymphocytic Leukemia (CLL) Binet stage A, untreated

Interventions

1. Intervention: randomised treatment with fludarabine (25 mg/m², days one to five, every 28 days, for a maximum of six courses) in high risk patients
2. Control: Watch and wait

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Fludarabine

Primary outcome measure

Progression-free survival

Secondary outcome measures

1. Overall survival
2. Quality of life
3. Incidence of infections

Overall study start date

01/07/1997

Completion date

30/09/2004

Eligibility**Key inclusion criteria**

1. Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) in Binet stage A
2. Initial diagnosis within the last three years
3. No previous therapy
4. Age between 18 and 75 years
5. Eastern Cooperative Oncology Group (ECOG) status zero to two
6. Signed informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

320

Total final enrolment

539

Key exclusion criteria

1. Autoimmune cytopenia
2. Severe concomitant disease
3. Concomitant secondary neoplasia
4. Participation in another clinical trial

Date of first enrolment

01/07/1997

Date of final enrolment

30/09/2004

Locations

Countries of recruitment

Germany

Study participating centre

Kerpenerstr. 62

Cologne

Germany

50924

Sponsor information

Organisation

German CLL Study Group (GCLLSG) (Germany)

Sponsor details

Department of Internal Medicine I

University of Cologne

Cologne

Germany

50924

+49 221 4783988

cll-studie@uk-koeln.de

Sponsor type

Research organisation

Website

<http://www.dcllsg.de>

Funder(s)

Funder type

Charity

Funder Name

German Cancer Aid (Deutsche Krebshilfe), Bonn (Germany)

Funder Name

German Chronic Lymphocytic Leukemia Study Group (GCLLSG), Cologne (Germany)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2020	12/02/2020	Yes	No